linjc16/ctgov huggingface dataset:
Implementation of the Robson Classification of Cesearn Section in Sohag University Hospital

Study Overview
=================
Brief Summary
-----------------
Aim Of The Work find out the frequency and indications for CS in sohag university hospitals and to analyze them according to Robson' ten group classification. This would be helping in adopting suitable measures to reduce the CS rate and identifying various challenges in our setting.

Detailed Description
-----------------
Cesarean Section Is A Surgical Procedure Used to Deliver A Baby Through Incisions In The Abdomen And Uterus . The incidence of Caesarean deliveries is increasing every day passing faraway beyond WHO recommended rate of 15% for all deliveries(1). The rates of maternal morbidity and mortality are higher after CS compared to vaginal birth. CS is associated with an increased risk of abnormal placentation, uterine rupture, ectopic pregnancy, stillbirth, and preterm birth. therefor Increase rate of unnecessary caesarean sections has been a growing concern in most parts of the world,Worldwide Caesarean section rates have risen from around 7% in 1990 to 21% in 2021 and are projected to continue over current decade if this trend continuees,by 2030 the highest rates are likely to be in Eastern Asia(63),Latin America and the Caribbean (54),Western Asia (50), Northen Africa (48),Southern Europe (47) and Australia and New Zealand(45) . According to the latest survey , one in five women in the world now deliver by caesarean section .Egypt has the highest rate of Caesarean section of 54 % in the Eastern Mediterranean Region , with no furthermore improvement to maternal and child mortality rates(2).

Official Title
-----------------
Implementation of the Robson Classification of the Cesearn Section in Sohag University Hospital

Conditions
-----------------
Robson Classification System

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Pregnant women more than 28 wks who will be admitted for labour Exclusion Criteria: pregnant women less than 28wks pregnant women presented with rupture uterus

Ages Eligible for Study
-----------------
Minimum Age: 15 Years
Maximum Age: 45 Years

Sexes Eligible for Study
-----------------
Female

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Frequency of cesearn sections in sohag university hospital | Number of cesearn sections per year | Within 6 months |
A Minimally Invasive Surgery for Axillary Osmidrosis: Combined Liposuction With Subcutaneous Pruning

Study Overview
=================
Brief Summary
-----------------
Patients with axillary osmidrosis are treated with minimally invasive procedure combined tumescent liposuction with Subcutaneous Pruning. Effectiveness of this modified method in reducing odor is to be determined.

Detailed Description
-----------------
Patients with excessive malodor are recruited. They are surgically treated with minimally invasive procedure combined tumescent liposuction with Subcutaneous Pruning and followed up for 6-24 months to evaluate effectiveness sand side effect.

Official Title
-----------------
A Refined Minimally Invasive Procedure for Radical Treatment of Axillary Osmidrosis: Combined Tumescent Liposuction With Subcutaneous Pruning Through a Small Incision

Conditions
-----------------
Sweat Gland Diseases

Intervention / Treatment
-----------------
* Procedure: minimally invasive surgery


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: 18 years or older unpleasant odor from the axillae Willing and able to appear for all scheduled, post-operative visits Exclusion Criteria: under the age of 18 have undergone a prior surgical intervention inappropriate candidates for surgery due to medical or mental health reasons elect not to participate in the study

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 60 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: minimally invasive surgery<br>There is only one arm to this study. All patients will receive treatment with the minimally invasive surgery for their axillary bromidrosis | Procedure: minimally invasive surgery<br>* Subcutaneous fat and apocrine sweat glands were removed by suction under tumescent anesthesia,and the remaining tissue and glands, tightly attached to the epidermis-dermis interface, were completely removed with scissors through the initial small incision.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| To assess the effectiveness of the refined minimally invasive procedure for radical treatment of axillary osmidrosis using patient self-report assessments | the satisfaction of patients | up to 24 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Axillary osmidrosis, liposuction, minimally invasive surgery
Unknown Cause of Acute Liver Failure

Study Overview
=================
Brief Summary
-----------------
The purpose of the study is to evaluate the outcome and to determine predictive factors of patients admitted in a context of acute liver failure without identified cause.

Detailed Description
-----------------
Methodology: Multicentric French national cohort with prospective collection of data and constitution of biobank, in patients hospitalized in a context of acute liver failure without known cause at admission. Follow-up during 3 months for each patients. The primary objective is to determine predictive factors of early mortality. This study is an observational cohort and patients will received standard care during the follow-up.

Official Title
-----------------
Unknown Cause of Acute Liver Failure: Determination of Early Mortality Predictive Factors

Conditions
-----------------
Liver Failure, Unknown Etiology

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Acute liver failure defined by a PT<50% or INR>1.5; with or without hepatic encephalopathy; without cause identified at admission, and non A non B hepatitis; age>18 year old; signed an informed consent. Exclusion Criteria: chronic liver disease; Patient under guardianship

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| mortality |  | At 3 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Liver transplantation rate |  | At 3 months | 
| Overall survival rate |  | At 3 months | 
| post-transplant mortality rate |  | At 3 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
liver failure, etiology, liver transplantation
Radiofrequency Ablation Plus Botulinum Toxin Injection Versus Radiofrequency Ablation Only in Patients With Atrial Flutter

Study Overview
=================
Brief Summary
-----------------
The aim of this randomized study was to assess the effectiveness of endomyocardial botulinum toxin injection for preventing post-procedural atrial fibrillation in patients undergoing the radiofrequency ablation of atrial flutter.

Official Title
-----------------
Radiofrequency Ablation Plus Botulinum Toxin Injection Versus Radiofrequency Ablation Only in Patients With Atrial Flutter to Prevent Post-procedural Atrial Fibrillation

Conditions
-----------------
Atrial Flutter

Intervention / Treatment
-----------------
* Procedure: radiofrequency ablation
* Drug: Botulinum Toxin Type A injection


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age ≥ 18 years ECG documented paroxysmal or persistent AFL No prior documented history of AF Patient undergoing RFA of AFL. No indication (other than AFL) for continued anticoagulation with warfarin. No existing implantable cardiac device (pacemaker, defibrillator, cardiac resynchronization therapy device) Exclusion Criteria: A history of atrial fibrillation Previous AF ablation procedure Congestive heart failure Left Ventricle ejection fraction less than 35% Unwillingness to participate

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 70 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: RFA+BT injection<br>Transseptal puncture is performed by used standard endovascular approach. Injection of the botulinum toxin is performed in main anatomical zones of ganglionated plexuses of left atrium using Myostar catheter (Biosense Webster). | Procedure: radiofrequency ablation<br> <br> Drug: Botulinum Toxin Type A injection<br> <br> |
| Active Comparator: RFA<br>Externally-irrigated tip (5-mm tip, Celsius Thermo-Cool, Biosense Webster, Diamond Bar, CA, USA). Temperature-controlled RF delivery was performed with a maximum power output of 50 W and temperature limit of 50 C. The catheter was irrigated using 0.9% saline infusion at a ﬂow rate of 20-40 mL/min during RF delivery and 2 mL/min between applications using a commercially available pump (Cool Flow, Biosense Webster). | Procedure: radiofrequency ablation<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| number of paroxysms of atrial fibrillation |  | 1 year | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| AF burden |  | 1 year | 
| serious adverse events |  | 1 year |
US-CT Fusion for Post Implant Dosimetry

Study Overview
=================
Brief Summary
-----------------
Post implant dosimetry is an essential part of quality assurance after permanent seed prostate brachytherapy. CT imaging is the standard of assessment but due to contouring uncertainties, MR-CT fusion is preferred. This is not always available due to financial restrictions. This study explores the possibility of post implant US-CT fusion to improve contouring accuracy and potentially replace the use of MR-CT fusion.

Detailed Description
-----------------
25 participants undergoing permanent seed prostate brachytherapy will be approached to undergo collection of prostate US images at the completion of their procedure. This will add approximately 5 minutes to the duration of their brachytherapy procedure. The US study will not entail any discomfort or risk to participants as they are still under anesthesia for the implant procedure. The institution standard of care for quality assurance will be complied with, obtaining a CT and MRI of the prostate at 30 days after the procedure. These will be co-registered and analyzed in the normal fashion. In addition, the post implant US images will also be co-registered with the CT and the resulting dosimetric parameters compared.

Official Title
-----------------
Comparison Between Postoperative Ultrasound-CT Fusion With MRI-CT Fusion for Postimplant Dosimetry for Prostate LDR Permanent Seed Brachytherapy

Conditions
-----------------
Prostate Cancer

Intervention / Treatment
-----------------
* Diagnostic Test: transrectal ultrasound


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: localized prostate cancer suitable for permanent seed implant brachytherapy as either monotherapy or as a boost Exclusion Criteria: Unable to undergo MRI

Ages Eligible for Study
-----------------
Minimum Age: 40 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
Male

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Diagnostic Test: transrectal ultrasound|Use of US for post implant quality assessment|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Comparison of prostate dosimetry assessed by US-CT fusion with respect to the standard MR-CT fusion | Dosimetry will be calculated using 2 different imaging modalities (US vs MRI) and compared | 1 month | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Comparison of prostate volume assessed by 2 different imaging modalities | Assessment of prostate volume as contoured on US vs MRI post implant | 1 month | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
prostate cancer, brachytherapy, Quality assurance
Study to Assess Safety of AZD7762 Administered Alone and in Combination With Gemcitabine in Patients With Advanced Solid Malignancies

Study Overview
=================
Brief Summary
-----------------
This is an open-label, multi-center, dose-escalation, Phase I study to evaluate the safety, tolerability, and pharmacokinetics and to investigate biomarker changes of AZD7762 administered as a single intravenous unit and in combination with gemcitabine. The study is sponsored by AstraZeneca.

Official Title
-----------------
A Phase I Open Label Multi Center Dose Escalation Study to Assess Safety, Tolerability, and Pharmacokinetics of AZD7762 Administered as a Single Intravenous Agent and in Combination With Weekly Standard Dose Gemcitabine in Patients With Advanced Solid Malignancies

Conditions
-----------------
Solid Tumors

Intervention / Treatment
-----------------
* Drug: AZD7762
* Drug: Gemcitabine


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Histologically or cytologically confirmed malignancy that is metastatic or unresectable and for which standard curative or palliative measures do not exist or are no longer effective ECOG performance status of 0 or 1 Patient and tumor type must be suitable for treatment with weekly standard gemcitabine. Exclusion Criteria: Inadequate bone marrow reserve, inadequate liver function or impaired renal function Any troponin elevation (above normal range) Stage II, III, or IV cardiac status, according to New York Heart Association (NYHA) classification; recent history (ie, within 6 months) of coronary artery disease or arteriosclerotic cardiovascular disease (angina, myocardial infarction [MI]) Any prior anthracycline treatment

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: 1<br>AZD7762 monotherapy followed by AZD7762 + gemcitabine | Drug: AZD7762<br>* intravenous infusion<br>Drug: Gemcitabine<br>* weekly intravenous infusion<br>* Other names: Gemcitabine HCL;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| To assess the safety and tolerability of AZD7762 alone and in combination with Gemcitabine |  | Assessed after each course of treatment | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| To determine the single-dose (after the first single-agent dose) and combination-dose (afer the 2nd combination dose) pharmacokinetics (PK) of AZD7762. |  | Assessed after each course of treatment | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Mixed solid tumors
Assessment of the Force Frequency Relationship of the Myocardium After On-pump CABG Surgery

Study Overview
=================
Brief Summary
-----------------
The aim of the study is to determine whether increasing the heart rate by epicardial atrial pacing after surgery improves the contractile force of the myocardium. After complete weaning from CPB, several pressure-loops of the LV will be recorded at different levels of preload using transoesophageal echo, invasive blood pressure monitoring. The preload will be manipulated by adding fluid from the CPB reservoir or draining fluid into the CPB reservoir.

Conditions
-----------------
Adult Cardiac Surgery

Intervention / Treatment
-----------------
* Device: External Pacing Box


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: CABG only surgery Preopeartive LVEF ≥ 53 % Use of epicardial pacing wires to assist CPB weaning Exclusion Criteria: Contra-indication to TEE AV block at the time of CPB weaning Sinus rhythm less than 50 or more than 90 BPM after CPB weaning.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Spontaneous rhythm first<br>Stepwise preload increase by repeated administration of 100 mL of fluid during spontaneous rhythm and then stepwise preload reduction by repeated drainage of 100 mL of fluid during atrial pacing. | Device: External Pacing Box<br>* Atrial pacing using an external pacing box<br>|
| Experimental: Atrial pacing first<br>Stepwise preload increase by repeated administration of 100 mL of fluid during atrial pacing and then stepwise preload reduction by repeated drainage of 100 mL of fluid during spontaneous rhythm. | Device: External Pacing Box<br>* Atrial pacing using an external pacing box<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| End-systolic elastane of the left ventricle. |  | 30 minutes after CPB weaning |
Evaluation of the Causes and Disease Processes of Chronic Lung Disease

Study Overview
=================
Brief Summary
-----------------
Chronic lung diseases are disorders associated with abnormalities in any of the structures involved in the process of breathing and bringing oxygen into the lungs and blood. This includes abnormalities in the airways, lungs, blood vessels in and around the lungs, and the tissue covering the lungs (pleura). The purpose of this research study is to evaluate patients referred to the Cardiovascular and Pulmonary Branch of the National Heart, Lung, and Blood Institute (NHLBI) in order to; Develop a better understanding of the causes and disease processes involved in disorders of the lungs Identify patients eligible to participate in other P-CCMB research studies

Detailed Description
-----------------
The chronic lung diseases are those disorders associated with functional and/or structural derangement to the alveolar structures, airways, pulmonary blood vessels, pleura and/or mediastinum. The purpose of this project is to permit the comprehensive evaluation of patients referred to the Pulmonary Branch of the National Heart, Lung, and Blood Institute (NHLBI) in order to: (1) develop an understanding of the etiology and pathogenesis of these disorders; and (2) identify individuals who will be suitable candidates for other NHLBI protocols. Testing and procedures will only be performed when medically indicated for the purposes of making a diagnosis or obtaining information likely to be useful in the management of the subjects' disease or condition.

Official Title
-----------------
Comprehensive Evaluation of the Etiology and Pathogenesis of Chronic Lung Disease (Screening Protocol)

Conditions
-----------------
Pulmonary Disease

Participation Criteria
=================
Eligibility Criteria
-----------------
INCLUSION CRITERIA: Symptoms consistent with pulmonary disease. May have family history of lung disease. Patients with diseases of organs with known association with lung disease. Ranging in age from 7 to 90 years old. Pregnant and nursing women may participate in minimal risk procedures EXCLUSION CRITERIA: Persons with no clinical evidence of lung disease.

Ages Eligible for Study
-----------------
Minimum Age: 7 Years
Maximum Age: 90 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Group 1<br>Pulmonary Patients | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| N/A-screening protocol | Evaluate | 1 Visit | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Computed Tomography, Fiberoptic Bronchoscopy, Pulmonary Function Testing, Cardiopulmonary Exercise Testing, Allergen Skin Testing